Healthcare Industry News: Accentia Biopharmaceuticals
News Release - June 14, 2006
Respirics Announces Launch Of MD Turbo(TM)RALEIGH, N.C.--(HSMN NewsFeed)--June 14, 2006--Respirics Inc. announces the commercial launch of MD Turbo, a companion product designed to solve two of the biggest problems patients with Asthma & COPD have with their pressurized metered dose inhalers (pMDI). MD Turbo will be marketed in the United States by TEAMM Pharmaceuticals, Inc., a subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI ).
"The pMDI celebrates its 50th birthday this year, and yet many patients continue to struggle to use these devices correctly," says Gilbert S. Mott Jr., President and CEO of Respirics. "MD Turbo is the first accessory device that solves two major challenges patients have with proper pMDI use: coordination of inhaler actuation with the patient's inhalation, and the accounting for how much medication is in the inhaler at any given time. We're excited about bringing a product to market that we believe can improve respiratory care by solving these two problems."
Poorly timed inhaler use may lead to inadequate symptom relief for the patient. MD Turbo incorporates i-Point(TM), the company's proprietary inhalation technology, which triggers the release of medication when an inspiratory flow threshold has been reached by the user. The device works by automatically depressing the inhaler canister when the patient breathes, thereby coordinating the drug's delivery. Also, with a limited number of "puffs" in each pMDI, if a user doesn't account for every use, the risk of a patient using an empty inhaler exists. To solve this problem, MD Turbo has an electronic counter which allows patients to keep track of how much medication remains in their inhaler.
"We know that most inhalers, when used correctly, can be effective in treating patients with asthma; however, we also know that many patients don't use these devices correctly," says Dr. Arthur Gelb, Clinical Professor of Medicine at the UCLA School of Medicine, and a pulmonologist who has a private practice in Lakewood, California. "I'm delighted to see another tool available to help patients coordinate the actuation of their inhaler with an inspiratory breath. The inclusion of a dose counter can only help patients who often simply guess about how much medicine remains in their inhaler."
It is estimated that over 37 million people in the United States suffer from Asthma and COPD. Most of those diagnosed are treated with some type of inhaler, over 40 million of which are pMDIs. MD Turbo is available by prescription in pharmacies across the U.S. More information on MD Turbo can be found at www.mdturbo.com.
Respirics Inc. is a leading pulmonary drug delivery and development company located in Raleigh, North Carolina. The company has two proprietary delivery platforms, MD Turbo for use with metered dose inhalers, and Acu-Breathe(TM) single and multi-dose dry powder inhalers. Respirics combines proprietary inhalation technology with powder drug formulation expertise to develop unique drug delivery solutions. The company is committed to bringing effective, easy-to-use and affordable inhalation drug products to the patients who need them. For more information, visit www.respirics.com.
About Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. In addition, Accentia's growing specialty pharmaceutical business, TEAMM Pharmaceuticals, Inc. has a portfolio of currently marketed products plus a pipeline of additional products under development by third parties. For further information, please visit the company web site: www.accentia.net.
Forward Looking Statements
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Respirics, TEAMM and Accentia and any other statements relating to products, product candidates, regulatory approval, product launches and product development programs. Such statements may include, without limitation, statements with respect to the plans, objectives, expectations and intentions of Respirics, TEAMM and Accentia, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. All forward looking statements are qualified in their entirety by this cautionary statement, and there shall be no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.